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Abstract
Background and Aim: Currently, there is no molecular-targeted agent that has dem-
onstrated evidence of efficacy in patients with unresectable hepatocellular carcinoma
(u-HCC) who have developed resistance to treatment with lenvatinib (LEN). In this
real-world study, we aimed to investigate the therapeutic effect and safety of sorafenib
(SOR) in patients with u-HCC after progression on treatment with LEN.
Methods (Patients) and Results: A total of 13 patients with u-HCC (12 males and
1 female), who were treated with SOR after progression on LEN, were enrolled in this
retrospective study. Therapeutic efficacy was evaluated via contrast-enhanced comput-
erized tomography at 8 weeks after the initiation of SOR therapy according to modi-
fied response evaluation criteria in solid tumors (mRECIST) and RECIST. According
to mRECIST, the objective response rate (ORR) and disease control rate (DCR) were
15.3% (2/13) and 69.2% (9/13), respectively. According to RECIST, the ORR and
DCR were 0% (0/13) and 69.2% (9/13), respectively. The median progression-free
survival was 4.1 months. The median albumin-bilirubin scores did not deteriorate sig-
nificantly at 4, 6, and 8 weeks after initiation of SOR, compared with the scores at the
baseline. The most frequent grade 1 or 2 adverse events (AEs) were palmar–plantar
erythrodysesthesia, fatigue, diarrhea, and hypertension. There was no incidence of
grade 3 AEs.
Conclusion: Treatment with SOR may be effective for u-HCC after failure on LEN
and may not worsen the liver reserve.
Introduction
The clinical significance of molecular-targeted agents (MTAs) in
unresectable hepatocellular carcinoma (u-HCC) has increased dras-
tically since the results from phase III SHARP trial in 2007 were
obtained.1 A recent phase III REFLECT study demonstrated that
lenvatinib (LEN) was noninferior to sorafenib (SOR) as a first-line
systemic therapy for u-HCC.2 Based on these results, several
guidelines positioned LEN as a first-line treatment for u-HCC in
addition to SOR.3,4 Furthermore, the opportunities for the adminis-
tration of LEN in clinical practice have increased.5–7
In the phase III RESORCE trial, regorafenib (REG) dem-
onstrated survival benefit in u-HCC as a second-line systemic
therapy in patients progressing on SOR.8 The phase III CEL-
ETIAL study reported survival benefit of cabozantinib (CAB) in
patients with u-HCC after resistance to SOR.9 Recently, the
REACH-2 trial demonstrated that ramucirumab (RAM) showed
survival benefit in patients with u-HCC progressing on SOR and
baseline alpha fetoprotein (AFP) level of ≥400 ng/mL.10
According to these results, REG, CAB, and RAM were
positioned as a second-line treatment for u-HCC after the devel-
opment of resistance to SOR.8,9,10
However, there is no evidence of the effectiveness of
MTAs in u-HCC after progression on LEN. Hence, there is an
unmet need to search for more effective and less toxic therapeu-
tic approaches as second-line treatment for u-HCC after progres-
sion on LEN.
LEN is an MTA that targets vascular endothelial growth
factor receptors 1–3, fibroblast growth factor receptors 1–4,
platelet-derived growth factor receptor α, RET, and KIT.11,12
Conversely, the target genes of SOR are related to angiogenesis
such as VEGFR and PDGFR, as well as C-Raf, wild-type B-Raf,
and mutant B-Raf, which are involved in the MAPK pathway.13
Therefore, the target molecules of SOR partly differ from LEN
as it mainly targets genes related to angiogenesis. Thus, there is a
possibility that SOR can be used as a therapeutic agent after pro-
gression on treatment with LEN. In fact, we have reported that
LEN treatment is moderately effective as the second-line treat-
ment after progression on SOR.14
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Therefore, in this study, we aimed to investigate the thera-
peutic effect and safety of SOR in patients with u-HCC after pro-
gression on treatment with LEN.
Methods
Patient selection and diagnosis of hepatocellular
carcinoma. This retrospective, observational study evaluated
the efficacy and safety of SOR (Nexavar, Bayer Yakuhin Ltd.,
Osaka, Japan) monotherapy in patients with unresectable
advanced HCC after resistance to treatment with LEN. The study
was conducted at the Tokushima University between May 2019
and February 2020. This study was approved by the Ethics Com-
mittee of Tokushima University Hospital (Approval number;
3489) and was performed in compliance with the 1975 Declara-
tion of Helsinki. The inclusion criteria were based on those of
the SHARP trial. Briefly, the antitumor effect was evaluated
using conventional response evaluation criteria in solid tumors
(RECIST) for measuring treatment responses based on tumor
shrinkage, whereas tumor uptake in the arterial phase of contrast-
enhanced computed tomography (CT) was evaluated using
modified RECIST (mRECIST),15,16 an Eastern Cooperative
Oncology Group performance status (ECOG PS) score of 0 or
1,17 Barcelona Clinic Liver Cancer stages (BCLC) B or C
categorizations,18 and Child-Pugh class A. Written informed con-
sent was obtained from all patients. The diagnosis of HCC was
based on guidelines established by the Liver Cancer Study Group
of Japan.19 According to these guidelines, a diagnosis of HCC
was confirmed via histology or characteristic radiologic findings,
such as typical arterial enhancement of the tumor followed by a
washout pattern in the images of the portal venous phase or the
equilibrium phase obtained via dynamic spiral CT imaging or
contrast-enhanced magnetic resonance imaging.
Treatment with SOR. For patients with no risk factors, we
introduced the recommended initial dose of SOR of 400 mg
twice daily.1,20 The initial SOR dose was reduced by each attend-
ing physician according to factors such as bodyweight, age,
ECOG PS, and liver function.21,22 During SOR treatment, each
attending physician decided to reduce the daily dose of SOR
according to the grades of adverse events (AEs) or ECOG PS.
Measurement of hepatic reserve function. Hepatic
reserve function was assessed according to albumin-bilirubin
(ALBI) grading and Child-Pugh classification. ALBI grade was
calculated based on serum albumin and total bilirubin values,
using the following formula: [ALBI score = (log10 bilirubin
(μmol/L)× 0.66) + (albumin (g/L) × −0.085)], and defined by the
following scores: ≤−2.60 = Grade 1, >−2.60 to ≤−1.39 = Grade
2, and >−1.39 = Grade 3.23
Statistical analysis. Categorical variables were compared
using Fisher’s exact test, while continuous variables were com-
pared using Mann–Whitney and Kruskal-Walls tests. All signifi-
cance tests were two-tailed, and statistical significance was set at
P < 0.05. Kaplan–Meier plots of medians (with 95% confidence
interval [CI]) were used to estimate progression-free survival
(PFS) and overall survival (OS). All statistical analyses were
performed using Easy R (EZR) version 1.29 (Saitama Medical
Center, Jichi Medical University, Saitama, Japan).
Results
Patient characteristics. A total of 13 patients (12 males
and 1 female) with u-HCC, who were treated with SOR after
progression on LEN, were enrolled in this study. Baseline patient
characteristics are shown in Table 1. The median age of the
patients was 73 years (range, 55–83 years). Three patients were
found to be hepatitis B virus antigen-positive, and four were hep-
atitis C virus antibody-positive. The ECOG PS was 0 in nine
patients. The median AFP value was 112 ng/mL (range,
1–487 300 ng/mL). There were six and eight patients with Child-
Pugh scores of 5 and 6, respectively. All patients were found to
have an ALBI grade 2. SOR was initiated at BCLC stage B and
stage C in six and seven patients, respectively. Three patients
started SOR with the standard dose (800 mg), while 10 patients
started SOR with a reduced dose (400 mg).
Therapeutic efficacy of SOR. The median observation
period after initiation of SOR was 203 (50–335) days. For all the
patients, therapeutic efficacy was evaluated using contrast-
enhanced CT at 8 weeks after the initiation with SOR therapy
according to mRECIST and RECIST. As per mRECIST, no
patient had complete response (CR), two patients had partial
response (PR), seven patients had stable disease (SD), and four
patients had progressive disease (PD). The objective response
rate (ORR) and disease control rate (DCR) were 15.3% (2/13)
Table 1 Characteristics of patients with unresectable hepatocellular
carcinoma treated with sorafenib
Characteristics All (n = 13)
Age, (years), median [range] 73 [62–81]
Gender (male/female), n 11/2
Etiology (HBV/HCV/NBNC), n 3/4/6
ECOG PS (0/1), n 7/4
Platelets (104/μL), median [range] 11.2 [5.4–30.1]
M2BpGi (C.O.I) [range] 2.51 [0.44–14.6]
Child-Pugh score (5/6), n 6/7
ALBI Grade (1/2/3), n 0/13/0
Number of intrahepatic lesions (None/1/2–7/>7) 0/1/8/3
Maximum size of intrahepatic lesion
(None/≤50/>50) (mm)
0/10/3
Portal vein invasion (absent/present), n 10/3
Extrahepatic spread (absent/present), n 11/2
AFP (ng/mL), median [range] 104 [1–487 300]
AFP≧400 (yes/no) 5/8
BCLC stage (B/C), n 9/4
Previous treatment times of TAE/TACE [range] 1 [0–4]
Initial dose of sorafenib (800/400), (mg), n 3/10
AFP, alpha fetoprotein; ALBI, albumin-bilirubin; BCLC, Barcelona Clinic
Liver Cancer stages; ECOG PS, Eastern Cooperative Oncology Group
performance status; HBV, hepatitis B virus; HCV, hepatitis C virus;
M2BPGi mac-2 binding protein glycosylation isomer; NBNC, non-B
non-C; TACE, transcatheter arterial chemoembolization; TAE,
transcatheter arterial embolization.
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and 69.2% (9/13), respectively. As per RECIST, no patients had
CR and PR, nine patients had SD, and four patients had PD. The
ORR and DCR were 0% (0/13) and 69.2% (9/13), respectively
(Table 2). The median PFS of all enrolled patients was
4.1 months (95% CI: 2.1–9.2 months; Figure S1, Supporting
information). The median OS of 13 patients was not reached. Till
date, 76.9% (10/13) of the patients were identified as having
radiologic PD after treatment with SOR, of which 80% were
treatable after progression on treatment with SOR (REG 60%
[6/10], transcatheter arterial chemoembolization 20% [2/10]). Of
note, REG was initiated in accordance with the eligibility criteria
of the RESORCE study.
Transition of hepatic reserve function after initia-
tion of treatment with SOR. The transition of hepatic
reserve function after initiation of SOR for 8 weeks was evaluated
in all patients. The median ALBI scores did not deteriorate signifi-
cantly at 4, 6, and 8 weeks after initiation of SOR (4 weeks:
−2.16 ± 0.34, 6 weeks: −1.89 ± 0.39, 8 weeks: −1.98 ± 0.42),
compared with the baseline scores (−2.19 ± 0.33) (Fig. 1).
Adverse events. SOR-related AEs are shown Table 3. The
most common AEs were palmar-plantar erythrodysesthesia
(53.8%: 7/13), followed by fatigue (30.7%: 4/13), decreased
appetite (30.7%: 4/13), hypertension (30.7%: 4/13), diarrhea
(30.7%: 4/13), decreased platelet count (15.4%: 2/13), and dys-
phonia (15.4%: 2/13). Grade 4 AEs were not observed during the
observation period. In addition, there was no discontinuation cau-
sed by AEs.
Representative case. A 77-year-old male had been
followed up for non-alcoholic steatohepatitis. The patient was
referred to our department for recurrence of multiple HCC. The
cirrhosis was classified as Child-Pugh 5, and the stage of HCC
was BCLC stage B.
He initially received conventional transcatheter arterial
embolization (cTAE). However, contrast-enhanced CT images,
obtained 1 month after cTAE, revealed that lipiodol was washed
out from more than half of the HCC nodules. We then started
treatment with LEN. After about 12 months of LEN treatment,
the patient exhibited PD (according to mRECIST). When the
treatment with LEN resulted in PD, the AFP level was ≤400 ng/
mL, and hence, RAM could not be used. Therefore, we started
treatment with SOR. An enhanced CT examination, performed
8 weeks following SOR initiation, showed decrease in enhanced
lesions, and the case was judged as PR by mRECIST (Fig. 2a,b).





(%) (n = 13)
RECIST n
(%) (n = 13)
Complete response 0 (0) 0 (0)
Partial response 2 (0) 0 (0)
Stable disease 7 (53.8) 9 (69.3)




Disease control rate (%) 69.3 69.3
mRECIST, modified response evaluation criteria in solid tumors.
Figure 1 The transition of hepatic reserve function after initiation of
treatment with sorafenib at baseline, 2 weeks, 4 weeks, 6 weeks, and
8 weeks. n.s: not significant. ALBI, albumin-bilirubin
Table 3 Adverse events of sorafenib treatment
All (n = 13)
Event Any grade Grade 1 Grade 2 Grade 3 Grade 4
Palmar-plantar erythrodysesthesia 7 (53.8) 6 (46.1) 1 (7.7) 0 (0) 0 (0)
Fatigue 4 (30.7) 4 (30.7) 0 (0) 0 (0) 0 (0)
Decreased appetite 4 (30.7) 4 (30.7) 0 (0) 0 (0) 0 (0)
Hypertension 4 (30.7) 2 (15.4) 2 (15.4) 0 (0) 0 (0)
Diarrhea 4 (30.7) 2 (15.4) 2 (15.4) 0 (0) 0 (0)
Decreased platelet count 2 (15.4) 2 (15.4) 0 (0) 0 (0) 0 (0)
Dysphonia 2 (15.4) 2 (15.4) 0 (0) 0 (0) 0 (0)
Increased blood bilirubin 1 (7.7) 0 (0) 1 (7.7) 0 (0) 0 (0)
Elevated aspartate aminotransferase 1 (7.7) 1 (7.7) 0 (0) 0 (0) 0 (0)
Elevated alanine aminotransferase 1 (7.7) 1 (7.7) 0 (0) 0 (0) 0 (0)
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Discussion
In the present study, we showed the therapeutic efficacy and
safety of SOR as a second-line treatment option for u-HCC after
resistance to treatment with LEN. We also demonstrated that,
over the duration of treatment with SOR, no significant decrease
in ALBI score was observed. To our knowledge, this is the first
study to report the feasibility and therapeutic efficacy of SOR
after progression on LEN in a clinical setting.
Recently, LEN has been suggested as the first-line treat-
ment for u-HCC, in addition to SOR, as per several guidelines.
In addition, the opportunities for the administration of LEN in
clinical practice have increased.3,4 However, there is no treatment
option available for patients with u-HCC after progression on
LEN. Therefore, there is a need to search for effective and safe
treatment options for patients with u-HCC who progress
on LEN.
In the REACH study, RAM was reported to have signifi-
cantly extended the survival in cases of AFP >400 ng/mL, as a
second-line treatment, after progression on SOR.10 The study
reported DCR of 59.9%, and the median PFS of 2.8 months.
However, the effectiveness of RAM after progression on LEN
has not been fully investigated. Recently, Kuzuya et al. reported
the results of a small cohort study in which patients with u-HCC
with AFP >400 ng/mL were administered RAM treatment after
LEN failure and showed promising therapeutic efficacy and
safety, with DCR of 80%, median time to treatment progression
of 3.1 months, and the incidence of grade 3 AEs of 10%.24
However, considering the fact that, among the patients
who progressed after SOR, only 23.3% of patients were eligible
for RAM,25 it is likely that only a small number of cases could
initiate RAM as a second-line treatment following LEN owing to
the strict eligibility criteria (AFP >400 ng/mL). In contrast, when
SOR is administered as a second-line treatment after LEN, there
is no need to consider the AFP value, thus suggesting high feasi-
bility of SOR as a second-line treatment after LEN.
In our study, among the 45 patients who received LEN as
first-line treatment, 27 cases were identified as radiologic PD;
18 patients (66.7%) received subsequent therapies after LEN
treatment, including SOR (n = 13, 48.1%), RAM (n = 3, 11.1%),
and transcatheter arterial embolization (TAE) (n = 2, 7.4%),
while the remaining 9 cases were best supportive care (BSC).
Among the 27 cases of radiologic PD, only 29.6% of the patients
met the eligibility criteria for the administration of RAM,10 thus
indicating that a limited number of patients could receive RAM
as the second-line treatment option after LEN.
In the RESORCE study, treatment with REG as the
second-line sequential therapy resulted in a DCR of 65% and
median PFS of 3.1 months. The CELETIAL study showed that
treatment with CAB resulted in a DCR of 64% and median PFS
of 5.2 months. In our study, treatment with SOR resulted in a
DCR of 69.3% and median PFS of 4.1 months. Furthermore,
although the number of cases was small (n = 5), even in AFP
>400 ng/mL, which is the eligibility criterion of RAM, DCR was
80%, with a median PFS of 4.1 months. Therefore, our results
were comparable to the results of previous studies that reported
sequential therapy of MTAs in patients with resistance to SOR.
Interestingly, as shown in Figure 2a,b, the enhanced CT examina-
tion performed 8 weeks following SOR initiation showed a
decrease in enhanced lesions. Several articles have reported that
the decreased arterial enhancement during treatment with SOR
was related to the OS and could reflect a therapeutic response.26,27
Taken together, these results suggest that SOR could be also effec-
tive as a second-line treatment option for u-HCC.
The drug-related AEs reported in this study were mostly of
grade 1 or 2 severity. Moreover, in line with the results of SHARP
and the Asia-Pacific study, the most frequent AEs in this study
were grade 1 or 2 palmar-plantar erythrodysesthesia, fatigue, diar-
rhea, and hypertension. In addition, treatment with SOR showed a
different AE profile than LEN, and thus, SOR treatment could eas-
ily be initiated following treatment with LEN, which suggested that
treatment with SOR after progression on LEN was well-tolerated.
The hepatic reserve function at the initiation of MTA treat-
ment is essential in the treatment of u-HCC.28,29 In the present
study, no significant decrease was observed in the ALBI score
within 8 weeks after the initiation of SOR. These results suggest
that long-term survival can be expected when using SOR after
LEN failure and that it could be easy to subsequence to the third-
line MTAs. Moreover, we could initiate the treatment with REG
in 60% (6/10) of the patients after progression on SOR (10/13)
as third-line therapy, which showed the possibility of favorable
survival.
Figure 2 Representative case of a 77-year-old male with unresectable
hepatocellular carcinoma treated with sorafenib after progression on
lenvatinib. (a) A contrast-enhanced computed tomography examination
after lenvatinib failure showed multiple enhanced lesions.
(b) Enhancement lesions were decreased at 8 weeks after the adminis-
tration of sorafenib.
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The main limitations of our study were its retrospective
nature, small sample size, and the short observation period.
Therefore, future large-scale prospective studies are required to
confirm the findings of this study.
In conclusion, we demonstrated that treatment with SOR
after LEN failure could be useful for u-HCC. In addition, this
treatment strategy may not worsen the liver reserve during
treatment.
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